Picture of a sphere with binary code

Making Strathclyde research discoverable to the world...

The Strathprints institutional repository is a digital archive of University of Strathclyde research outputs. It exposes Strathclyde's world leading Open Access research to many of the world's leading resource discovery tools, and from there onto the screens of researchers around the world.

Explore Strathclyde Open Access research content

Guanine-nucleotide binding regulatory proteins as targets for novel drugs

Pyne, Nigel (1992) Guanine-nucleotide binding regulatory proteins as targets for novel drugs. Proceedings - Royal Society of Edinburgh. Section B: Natural environment, 99 (1-2). pp. 27-36. ISSN 0308-2113

Full text not available in this repository. (Request a copy from the Strathclyde author)


Guanine-nucleotide regulatory binding proteins (G-proteins) serve to transduce information from agonist-bound receptor complexes to either effector enzymes or ion-channels. Drugs that perturb the function of G-proteins may do so by one of four mechanisms. (i) They may exert negative intrinsic activity toward the G-protein. For instance, we have shown that incubation of isolated plasma-membranes with the beta-adrenoceptor blocking drug sotalol blocked both GTP-stimulated and isoprenaline-stimulated adenylyl cyclase. This suggests that the empty beta-adrenoceptor is capable of tonically stimulating G(s-alpha) and therefore adenylyl cyclase; that is, empty beta-adrenoceptors promote GDP-GTP exchange. (ii) They may perturb the GDP-GTP exchange reaction. For instance, certain PDE inhibitors, including SKF 94836 and rolipram, stimulate a marked increase in the pertussis toxin-catalysed NAD+-dependent ADP-ribosylation of G(i-alpha). This effect is similar to that of GDP, which promotes stabilisation of the alpha-beta-gamma holomer of G(i). The effect of these PDE inhibitors is completely reversed by GppNHp, which triggers alpha-beta-gamma dissociation by binding to the guanine-nucleotide binding domain of the G-protein. PDE inhibitors may serve as a class of drugs which perturb GDP-GTP exchange. (iii) They may trigger uncoupling of receptor-G-protein complexes. For instance, the polycationic drug mastoparan binds to the C-terminal end of the G-protein and mimics the effect of receptor activation by promoting GTP-gamma-S binding, a reduction in pertussis toxin-catalysed ADP-ribosylation, and inhibition of adenylyl cyclase activity. Other agents, such as polyanionic drugs, bind to the receptor to promote uncoupling of receptor-mediated activation of certain G-proteins. (iv) They may alter the cross-talk mechanisms that operate between different receptor signalling systems. For instance, protein kinase C promotes the phosphorylation and inactivation of G(i). This leads to an unopposed stimulation of adenylyl cyclase via G(S) and, therefore, enhanced sensitivity to agents such as glucagon. Protein kinase C inhibitors may be usefully exploited to modulate these processes which appear to be abberant in certain disease-states.